Phathom Pharmaceuticals, Inc. (PHAT) has a consensus analyst rating of Buy, based on 9 analysts covering the stock. Of those, 8 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for PHAT is $23.33, representing a +84.1% upside from the current price of $12.67. Price targets range from a low of $16.00 to a high of $28.00.
